Unichem Laboratories share news, announcements and annual reports
NSE: UNICHEMLABBSE: 506690Pharmaceuticals & BiotechnologySmall Cap
Unichem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1963 on BSE, Feb 2001 on NSE
Last close ₹488.80up ₹7.70 (1.60%)BSE ₹486.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹481.10.
28 Oct: open ₹489.95, high ₹501.85, low ₹480.00
52-week range of traded prices to 28 Oct 2026
₹278.20Low, 30 Mar 2026₹687.20High, 9 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,441 Cr1,036th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.29
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 34.46
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.27
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 35,53933.1% delivered
Unichem Laboratories disputes and clarifications
22 filed, newest first.
Sep 2026
19 Sep · Legal
Aug 2026
26 Aug · Legal
The exchange asked on 25 Aug 2026
Jul 2026
29 Jul · Legal
10 Jul · Legal
The exchange asked on 10 Jul 2026
Jun 2026
11 Jun · Legal
The exchange asked on 10 Jun 2026
Oct 2024
23 Oct · Legal
The exchange asked on 22 Oct 2024
Apr 2023
14 Apr · Legal
The exchange asked on 13 Apr 2023
Jun 2021
10 Jun · Legal
Exchange has sought clarification from Unichem Laboratories Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Dec 2020
8 Dec · Legal
The exchange asked on 7 Dec 2020
Jul 2020
14 Jul · Legal
Exchange has sought clarification from Unichem Laboratories Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Mar 2020
30 Mar · Legal
The exchange asked on 27 Mar 2020
Jun 2018
21 Jun · Legal
Exchange has sought clarification from Unichem Laboratories Limited with respect to announcement dated 20-Jun-2018, regarding " Unichem Laboratories Limited has informed the Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem's Abbreviated New Drug Application for generic tadalafil (Cialis). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty etc; 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation; The response of the Company is awaited.
Oct 2015
Sep 2015
4 Sep · Legal
Clarification by Unichem Laboratories LimitedSubstantial increase in trading volumes have been observed in Unichem Laboratories Limited.The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Unichem Laboratories Limited has vide its letter inter-alia stated, "We wish to inform you that, to the best of our knowledge and understanding there is no price sensitive information which is pending dissemination by the company through the exchange to the investors / general public, which would have a bearing on the price/ volume behavior of the Company's Equity Shares."
Aug 2015
Apr 2015
17 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Unichem Laboratories Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Unichem Laboratories Limited has vide its letter inter-alia stated," There is no price sensitive information which is pending for dissemination to the investors/general public, by the Company through the exchange which would have a bearing on the price/ volume behaviour of the Company's equity share."
Dec 2014
12 Dec · Legal
Exchange had sought clarification from Unichem Laboratories Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "We have been aware of the concerns with GVK Biosciences and have been cooperating with the European authorities, via our subsidiary Unichem Ireland. Of the products referred to, none of them are currently on sale in Germany from Unichem, therefore this action will have no material impact on the overall performance of Unichem Laboratories Limited".11 Dec · Legal
Exchange has sought clarification from Unichem Laboratories Limited with respect to recent news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2010
18 Oct · Legal
Unichem Laboratories Limited had informed the Exchange that the Board of Directors in its Board Meeting held on October 16, 2010 declared an Interim Dividend of Rs. 1.20/- (60%) per equity share of Rs. 2/- (post split face value) for the year 2010-11. The Company has now informed the Exchange that percentage wise the Interim Dividend declared will remain same i.e. 60% even on Pre-Split face value of Rs. 5/- each i.e. Rs. 3/- per equity share of Rs. 5/- each. Further, dividend on fractional entitlements on account of split will be added to the proceeds arising out of sale of shares on account of such entitlements and paid to the eligible shareholders.